Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TOI 
Oncology Institute Inc (TOI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: TOI (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 278.17% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 285.19M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.13 | 52 Weeks Range 0.13 - 4.50 | Updated Date 09/14/2025 |
52 Weeks Range 0.13 - 4.50 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.53% | Operating Margin (TTM) -9.36% |
Management Effectiveness
Return on Assets (TTM) -17.28% | Return on Equity (TTM) -651.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 358052539 | Price to Sales(TTM) 0.67 |
Enterprise Value 358052539 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 0.84 | Enterprise Value to EBITDA -1.87 | Shares Outstanding 93504800 | Shares Floating 77563139 |
Shares Outstanding 93504800 | Shares Floating 77563139 | ||
Percent Insiders 8.88 | Percent Institutions 40.72 |
Upturn AI SWOT
Oncology Institute Inc
Company Overview
History and Background
The Oncology Institute, Inc. (TOI) was founded in 2007. It has grown to be a significant provider of cancer care, focused on community-based oncology practices, with a mission to advance cancer care in community settings.
Core Business Areas
- Cancer Treatment Services: Provides comprehensive cancer care, including chemotherapy, radiation therapy, immunotherapy, and targeted therapies.
- Diagnostic Imaging: Offers diagnostic services to detect and monitor cancer progression.
- Supportive Care: Provides supportive care services to patients and their families, including counseling, nutrition guidance, and pain management.
- Clinical Trials: Conducts clinical trials to evaluate new cancer treatments and improve patient outcomes.
Leadership and Structure
TOI is led by a management team with experience in healthcare administration and oncology. The company operates through a network of affiliated oncology practices.
Top Products and Market Share
Key Offerings
- Chemotherapy: Traditional chemotherapy drugs. Market share data is not publicly available at a granular level. Competitors include providers offering similar treatments through different networks or hospitals.
- Immunotherapy: Advanced immunotherapy treatments. Market share data is not publicly available at a granular level. Competitors include providers offering similar treatments through different networks or hospitals.
- Radiation Therapy: Radiation treatments using various technologies. Market share data is not publicly available at a granular level. Competitors include providers offering similar treatments through different networks or hospitals.
Market Dynamics
Industry Overview
The oncology industry is characterized by increasing demand for cancer care services, driven by an aging population and advancements in treatment options. It is also experiencing consolidation with providers consolidating into larger networks.
Positioning
TOI focuses on community-based oncology practices. The company's competitive advantage lies in its integrated care model and emphasis on patient-centric care. TOI strives to bring academic-level cancer care to community settings.
Total Addressable Market (TAM)
The global oncology market is estimated to be several hundred billion dollars annually. TOI is positioned to capture a share of this market through its network of cancer centers.
Upturn SWOT Analysis
Strengths
- Integrated care model
- Community-based focus
- Experienced management team
- Focus on value-based care
Weaknesses
- High operating expenses
- Dependence on reimbursement rates
- Competition from larger healthcare providers
- Reliance on key personnel
Opportunities
- Expansion into new geographic markets
- Partnerships with other healthcare providers
- Increased adoption of value-based care models
- Growing demand for cancer care services
Threats
- Changes in reimbursement policies
- Increased competition
- Rising healthcare costs
- Economic downturns
Competitors and Market Share
Key Competitors
- USON
- CRH
- HCA
Competitive Landscape
TOI competes with other oncology providers, hospitals, and academic medical centers. The competitive landscape is fragmented and competitive, with companies differentiating themselves based on service offerings, geographic reach, and pricing.
Growth Trajectory and Initiatives
Historical Growth: TOI has experienced growth through acquisitions and expansion of its network of cancer centers.
Future Projections: Future growth is expected to be driven by continued expansion into new markets and increased adoption of value-based care models. Analyst estimates vary and are subject to change.
Recent Initiatives: Recent strategic initiatives include expanding telemedicine services and developing new partnerships with other healthcare providers.
Summary
The Oncology Institute operates community-based cancer centers focused on patient-centric care. While they emphasize value-based care and growth through expansion, they face significant competition and reimbursement challenges. Their integrated care model is a strength, but dependence on reimbursement rates and competition remain key concerns. They need to be vigilant about managing operating expenses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Press Releases
- Industry Reports
- Analyst Estimates
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market share data might be approximate and based on limited public information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oncology Institute Inc
Exchange NASDAQ | Headquaters Cerritos, CA, United States | ||
IPO Launch date 2021-11-15 | CEO & Executive Director Dr. Daniel Virnich FACHE, M.B.A., M.D. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 825 | Website https://theoncologyinstitute.com |
Full time employees 825 | Website https://theoncologyinstitute.com | ||
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.